Skip to main content

Florinef Acetate Disease Interactions

There are 22 disease interactions with Florinef Acetate (fludrocortisone).

Major

Corticosteroids (applies to Florinef Acetate) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, mask the symptoms of infection, and reactivate or exacerbate latent infections (e.g., hepatitis B, amebiasis). Secondary infections may be more likely to develop. In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted. However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency. Removal of external steroid during periods of stress may be detrimental to these patients.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 10 references
Moderate

Corticosteroids (applies to Florinef Acetate) (+) tuberculin test

Moderate Potential Hazard, High plausibility. Applicable conditions: Tuberculosis -- Latent, History - Tuberculosis

In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease. Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity. During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
View all 9 references
Moderate

Corticosteroids (applies to Florinef Acetate) cirrhosis

Moderate Potential Hazard, Moderate plausibility.

Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents. Patients with cirrhosis should be monitored more closely for excessive cortisol effects. Dosage adjustments may be required in these patients.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
View all 9 references
Moderate

Corticosteroids (applies to Florinef Acetate) depression/psychoses

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis

Corticosteroids may aggravate the symptoms of psychosis and emotional instability. Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) diabetes

Moderate Potential Hazard, High plausibility. Applicable conditions: Diabetes Mellitus, Abnormal Glucose Tolerance

Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia. Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) electrolyte imbalance

Moderate Potential Hazard, High plausibility. Applicable conditions: Seizures, Hypernatremia, Hypokalemia, Hypocalcemia, Electrolyte Abnormalities

Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention. These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone. The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities. However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods. All corticosteroids also increase excretion of calcium and can cause hypocalcemia. Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances. Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) fluid retention

Moderate Potential Hazard, High plausibility. Applicable conditions: Hypertension, Renal Dysfunction, Congestive Heart Failure

Corticosteroids may cause hypernatremia, hypokalemia, fluid retention, and elevation in blood pressure. Large doses of any corticosteroid can demonstrate these effects, particularly if given for longer periods. Therapy with corticosteroids should be administered cautiously in patients with preexisting fluid retention, hypertension, congestive heart failure, and/or renal dysfunction. Dietary sodium restriction and potassium supplementation may be advisable.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) GI perforation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diverticulitis, Intestinal Anastomoses, Ulcerative Colitis

Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods. They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis. Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) hyperadrenocorticalism

Moderate Potential Hazard, High plausibility. Applicable conditions: Hyperadrenocorticism, Hyperaldosteronism, Adrenal Tumor

Corticosteroids mimic the effects of endogenous cortisol and aldosterone. Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) hyperlipidemia

Moderate Potential Hazard, Moderate plausibility.

Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods. Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.

References

  1. Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42
  2. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  3. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  4. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  6. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  7. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  8. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  9. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  10. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
View all 10 references
Moderate

Corticosteroids (applies to Florinef Acetate) hypothyroidism

Moderate Potential Hazard, Moderate plausibility.

Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents. Patients with hypothyroidism should be monitored more closely for excessive cortisol effects. Dosage adjustments may be required secondary to changes in their thyroid condition.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) liver disease

Moderate Potential Hazard, High plausibility.

Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease. Dosage adjustments may be necessary in these patients.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975): 183-5
  3. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  4. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  6. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  7. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  8. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  9. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  10. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) MI

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Myocardial Infarction, Post MI Syndrome

The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction. Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) myasthenia gravis

Moderate Potential Hazard, High plausibility.

Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting. Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages. Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached). Improvement may be delayed and gradual. Thus, it is important not to discontinue therapy prematurely.

References

  1. Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison's Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division (1998):
Moderate

Corticosteroids (applies to Florinef Acetate) myopathy

Moderate Potential Hazard, High plausibility. Applicable conditions: Myoneural Disorder

Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents. Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents. Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses. Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea. In some cases, it has resulted in quadriparesis. Elevations of creatine kinase (CK) may also occur, albeit infrequently. After withdrawal of corticosteroid therapy, recovery may be slow and incomplete. Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy. The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness. If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) ocular herpes simplex

Moderate Potential Hazard, Moderate plausibility.

Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation. Corticosteroids are not recommended for patients with active ocular herpes simplex.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) ocular toxicities

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension, Cataracts

Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. widdershoven j, lambert w, motohara k, monnens l, de leenheer a, Matsuda I, endo f "Plasma concentrations of vitamin K1 and PIVKA-II in bottle-fed and breast-fed infants with and without vitamin K prophylaxis at birth." Eur J Pediatr 148 (1988): 139-42
  12. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 12 references
Moderate

Corticosteroids (applies to Florinef Acetate) osteoporosis

Moderate Potential Hazard, High plausibility.

Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy. In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures. Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis. Adverse skeletal effects may be minimized by alternate-day or intermittent administration. Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) PUD

Moderate Potential Hazard, High plausibility. Applicable conditions: Peptic Ulcer, History - Peptic Ulcer

Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods. However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers. Delayed healing of ulcers has also been reported. Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding. Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) scleroderma

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Systemic Sclerosis

In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production. Renal failure may ensue. Therapy with corticosteroids should be administered cautiously in patients with scleroderma. In addition, they should be limited to short-term use.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison's Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division (1998):
View all 10 references
Moderate

Corticosteroids (applies to Florinef Acetate) strongyloidiasis

Moderate Potential Hazard, High plausibility.

Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host. In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients. For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references
Moderate

Corticosteroids (applies to Florinef Acetate) thromboembolism

Moderate Potential Hazard, Low plausibility. Applicable conditions: History - Thrombotic/Thromboembolic Disorder, Thrombotic/Thromboembolic Disorder

Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis. Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.

References

  1. "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc PROD (2001):
  2. "Product Information. Deltasone (prednisone)." Pharmacia and Upjohn PROD (2001):
  3. "Product Information. Decadron (dexamethasone)." Merck & Co., Inc PROD (2001):
  4. "Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc PROD (2001):
  5. "Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn PROD (2001):
  6. "Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc PROD (2001):
  8. "Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb PROD (2001):
  9. "Product Information. Celestone (betamethasone)." Schering Corporation PROD (2001):
  10. "Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc. SUPPL-5 (2021):
  11. "Product Information. Agamree (vamorolone)." Santhera Pharmaceuticals (US) (2023):
View all 11 references

Florinef Acetate drug interactions

There are 566 drug interactions with Florinef Acetate (fludrocortisone).

Florinef Acetate alcohol/food interactions

There are 2 alcohol/food interactions with Florinef Acetate (fludrocortisone).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.